Form 4: Quoin Pharmaceuticals CFO Buys Shares
Insider Transaction (Form 4)
Sally Bridget Lawlor, Chief Financial Officer of Quoin Pharmaceuticals, Ltd., purchased 15,366 shares of common stock on August 31, 2026 for $4.88 per share.
Summary
- Open-market purchase: acquired 10,244 ADSs at $4.88 ($49,991) on August 31, 2026; holds 10,684 after (Direct).
- Open-market purchase: acquired 5,122 Ordinary Warrants (Right to Buy) on August 31, 2026; holds 5,122 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $49,991, committing personal capital to the stock.
Insider Transactions
Sally Bridget Lawlor — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Open-market purchase | ADSs | 10,244 | $5 | $50.0K | 10,684 |
| 2026-08-31 | Open-market purchase | Ordinary Warrants (Right to Buy) | 5,122 | — | — | 5,122 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Open-market purchase (10,244 shares) |
| 2026-08-31 | Open-market purchase (5,122 shares) |
Keywords
insider transaction, Form 4, QNRX, Quoin Pharmaceuticals, Ltd., bullish, Sally Bridget Lawlor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.